Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant

Br J Haematol. 2019 Feb;184(4):690-693. doi: 10.1111/bjh.15169. Epub 2018 Mar 12.

Deepika S Darbari^{1

2

3

4}, Jaquette Liljencrantz^{4

5}, Austin Ikechi⁶, Staci Martin^{4

7}, Marie Claire Roderick^{4

7}, Courtney D Fitzhugh^{3

4}, John F Tisdale^{4

8}, Swee Lay Thein^{3

4}, Matthew Hsieh^{4

8}

¹ Division of Hematology and Oncology, Children's National Medical Center, Washington, DC, USA.
² The George Washington University School of Medicine, Washington, DC, USA.
³ Sickle Cell Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA.
⁴ National Institutes of Health, Bethesda, MD, USA.
⁵ Pain and Integrative Neuroscience Laboratory, National Center for Complementary and Integrative Health, Bethesda, MD, USA.
⁶ Ohio State University, Columbus, OH, USA.
⁷ National Cancer Institute, Rockville, MD, USA.
⁸ Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.

No abstract available

Keywords: haematopoietic stem cell transplant; opioids; pain; sickle cell disease.

Publication types